AstraZeneca snagged $250 million-plus for its cancer drug Zoladex in the U.S., where it brought in only $69 million last year. The deal, AZ's latest slim-…

Stada said it has a third suitor in the mix to buy the company, and Bernstein analyst Ronny Gal thinks he may know who it is.

The impending approval of Momenta's copy of Teva’s long-acting version of blockbuster Copaxone is now expected to be delayed.

As activist investor William Ackman, a thorn in Zoetis' side for two years, reported that he'd sold off his stake, the animal health giant reported…

Regeneron expects Eylea to grow this year at a rate well below Wall Street expectations. But don't ask CEO Len Schleifer to explain.

GlaxoSmithKline CEO Andrew Witty finally laid out just how much damage he expects Advair knockoffs to do this year.

If you’re looking for new drama at Sanofi this year, you might just be disappointed. The French drugmaker said Wednesday it’s expecting no big financial swings…

CEO John Milligan was asked to ponder his $30 billion in 2016 revenue—and answer this key question: Can you "grow company without an acquisition?”

The same day that the company showed CEO Erez Vigodman the door, the drugmaker was said to be under investigation by Israeli police for bribing foreign…

Financials